Frequency and risk factors of sarcopenia in the elderly people

Aim. To determine the frequency and assess the risk factors of sarcopenia (SP) in elderly people living at home.

Materials and methods. The study included 230 people aged 65 years and older who lived at home and were observed in outpatient clinic. To detect SP, grip strength was measured and muscle mass was determined using dual-energy absorptiometry (DXA). Severe SP was diagnosed based on the results of Short physical performance battery (SPPB) and the “Up and Go” test. The diagnosis of SP was made according to the criteria of EWGSOP2 (2018). The laboratory examination included clinical and biochemical blood analysis, determination of the level of 25 (OH) D.

Results. Probable SP was found in 64.8 %, confirmed SP – in 28.7 %, and severe SP – in 21.3 % of older people. The frequency of SP increased with age from 19.6 % in 65–74 years to 52.9 % in 85 years and older (p <0.05). The results of multivariate analysis showed that the probability of SP increased with a BMI of less than 25 kg / m² (OR 5,459; 95 % CI: 1,939–15,369; p = 0.0013), severe comorbidity calculated by the Charlson index (OR 5,178; 95 % CI: 1,597–14,128; p = 0.0030) and the presence of such laboratory indicators like level 25 (OH) D less than 20 ng / ml (OR 4,989; 95 % CI: 1,321–12,626; p = 0.0420), total protein less than 64 g / l (OR 8,567; 95 % CI: 2,658–27,617; p = 0.00032), CRP more than 5 mg / l (OR 14,279; 95 % CI: 3,511–58,071; p = 0.00020) and moderately reduced renal function (GFR <60 ml / min / 1.73 m (OR 12,108; 95 % CI: 3,944–37,170; p = 0.00001).

Conclusions. Among elderly people, a high frequency (28.7 %) of SP was detected, which increased with age. A BMI of less than 25 kg / m², a deficiency of 25(OH)D, total protein level of less than 64 g / l and CRP of more than 5 mg / l, a decrease in GFR of less than 60 ml / min were associated with the presence of SP.

1. Rosenberg I. Summary comments. Am J Clin Nutr 1989;50(5):1231–3. DOI: 10.1093/ajcn/50.5.1231

2. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M. et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412–23. DOI: 10.1093/ageing/afq034

3. Cruz-Jentoft A.J., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31. DOI: 10.1093/ageing/afy169

4. Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 2017;16(16):21. DOI: 10.1186/s40200-017-0302-x

5. Reiss J., Iglseder B., Alzner R. et.al. Consequences of applying the new EWGSOP2 guideline instead of the former EWGSOP guideline for sarcopenia case finding in older patients. Age Ageing 2019;48(5):719–24. DOI: 10.1093/ageing/afz035

6. Yang M., Liu Y., Zuo Y. et al. Sarcopenia for predicting falls and hospitalization in community dwelling older adults: EWGSOP versus EWGSOP2. Sci Rep 2019;9(1):17636. DOI: 10.1038/s41598-019-53522-6

7. Kurose S., Nishikawa S., Nagaoka T. et al. Prevalence and risk factors of sarcopenia in community-dwelling older adults visiting regional medical institutions from the Kadoma Sarcopenia Study. Sci Rep 2020;10(1):19129. DOI: 10.1038/s41598-020-76185-0

8. Espinel-Berm-dez M.C., Ramírez-García E., García‐Peña C. et al. Prevalence of sarcopenia in community‐dwelling older people of Mexico City using the EGWSOP (European Working Group on Sarcopenia in Older People) diagnostic criteria. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(2):e00009. DOI: 10.17987/jcsm-cr.v2i2.9

9. Cruz-Jentoft A.J., Landi F., Schneider S.M. et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43(6):748–59. DOI: 10.1093/ageing/afu115

10. Diz J.B., Leopoldino AA., Moreira B.S. et al. Prevalence of sarcopenia in older Brazilians: a systematic review and metaanalysis. Geriatr Gerontol Int 2017;17(1):5–16. DOI: 10.1111/ggi.12720

11. Lutski M., Weinstein G., Tanne D. et al. Overweight, obesity, and late-life sarcopenia among men with cardiovascular disease, Israel. Prev Chronic Dis 2020;17:E164. DOI: 10.5888/pcd17.200167

12. Scott D., Johansson J., Ebeling P.R. Adiposity without obesity: associations with osteoporosis, sarcopenia, and falls in the Healthy Ageing Initiative cohort study. Obesity (Silver Spring) 2020;28(11):2232–41. DOI: 10.1002/oby.22984

13. Kim H., Suzuki T., Kim M. et al. Incidence and predictors of sarcopenia onset in community-dwelling elderly Japanese women: 4-year follow-up study. J Am Med Dir Assoc 2015;16(1):85. e1–8. DOI: 10.1016/j.jamda.2014.10.006

14. Yu R., Wong M., Leung J. et al. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. Geriatr Gerontol Int 2014;14(1):15–2. DOI: 10.1111/ggi.12220

15. Steffl M., Bohannon R. W., Sontakova L. et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 2017:12:835–45. DOI: 10.2147/CIA.S132940

16. Volpato S., Bianchi L., Cherubini A. et al. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm. J Gerontol A Biol Sci Med Sci 2014;69(4):438–46. DOI: 10.1093/gerona/glt149

17. Therakomen V., Petchlorlian A., Lakananurak N. Prevalence and risk factors of primary sarcopenia in community-dwelling outpatient elderly: a cross-sectional study. Sci Rep 2020; 11;10(1):19551. DOI: 10.1038/s41598-020-75250-y

18. Luo J., Quan Z., Lin S. et al. The association between blood concentration of 25- hydroxyvitamin D and sarcopenia: a metaanalysis. Asia Pac J Clin Nutr 2018;27(6):1258–70. DOI: 10.1111/ced.13381

19. Matheï C., Pottelbergh G.V., Vaes B. et al. No relation between vitamin D status and physical performance in the oldest old: results from the Belfrail study. Age Ageing 2013;42(2):186–90. DOI: 10.1093/ageing/afs186

20. Can B., Kara O., Kizilarslanoglu M.C. et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res 2017;29(4):745–52. DOI: 10.1007/s40520-016-0626-2

21. Moreno-Gonzalez R., Corbella X., Mattace-Raso F. et al. SCOPE investigators. Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria: The Screening for CKD among Older People across Europe (SCOPE) study. BMC Geriatr 2020;20(1):327. DOI: 10.1186/s12877-020-01700-x

22. Bano G., Trevisan C., Carraro S. et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas 2017;96:10–15. DOI: 10.1016/j.maturitas.2016.11.006

23. Shokri-Mashhadi N., Moradi S., Heidari Z. et al. Association of circulating C-reactive protein and high-sensitivity C-reactive protein with components of sarcopenia: a systematic review and meta-analysis of observational studies. Exp Gerontol 2021;150:111330. DOI: 10.1016/j.exger.2021.111330

24. Tang T., Xie L., Tan L. et al. Inflammatory indexes are not associated with sarcopenia in Chinese community-dwelling older people: a cross-sectional study. BMC Geriatr 2020;20(1):457. DOI: 10.1186/s12877-020-01857-5